Visit Definiens at booth #423 at the Molecular Med-Tri-Con conference, February 16-18 to learn about Definiens’ comprehensive range of digital and molecular pathology solutions for imaging and quantifying biomarkers in tissue sections. At the conference we will be showcasing the latest imaging and analysis technologies which are revolutionizing research pathology, leading to breakthroughs in personalized medicine and cancer research.
And don’t miss our luncheon presentation on Monday, February 16, where you can hear Dr. Sharon Moulis, Director of Tissue Diagnostics Alliances present her approach to developing IHC assays for clinical trial patient stratification.
How to Develop Fit-for-Purpose IHC Assays to Enable Clinical Trial Patient Stratification
Sharon Moulis, PhD, Director, Tissue Diagnostics Alliances, Definiens
Digital Pathology Track
Monday, February 16th
We look forward to seeing you in San Francisco!